NEWSROOM

Biotechnology

EASY ENERGY SYSTEMS TO EXHIBIT AT ORGANIC GROWERS SUMMIT IN MONTEREY, CA

Nov 21, 2023

Mankato, Minnesota, November 21, 2023 - Digital Utilities Ventures, Inc. (OTC: DUTV), announces that its planned future affiliate, Easy Energy Systems, Inc., will be exhibiting at the Organic Growers Show in Monterey on November 29-30. The summit provides growers firsthand knowledge and information in a variety of areas ranging from Agtech to food safety to sustainability. Through engaging educational sessions, insightful Keynote presentations and a trade show floor featuring...

BioStem Technologies Reports Third Quarter 2023 Operating and Financial Results

Nov 14, 2023

Company to Host a Conference Call and Webcast on November 14, 2023, at 10:30 am EDT POMPANO BEACH, FLORIDA, November 13, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today reported financial results for the quarter ended September 30, 2023. Jason Matuszewski, Chief Executive Officer of BioStem Technologies Inc. said, “2023 has been a remarkable year of growth...

Lipella Pharmaceuticals Granted FDA Orphan Designation for Oral Graft-versus-Host Disease Drug

Nov 10, 2023

“GvHD affects approximately 30,000 Americans and oral GvHD causes significant oral pain and discomfort, making it difficult for patients to eat, drink and speak. Oral GvHD is a great unmet need in cancer survivors.” Dr. Michael Chancellor, Chief Medical Officer at Lipella Pharmaceuticals Pittsburgh, PA, November 10, 2023 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our, “us” or the “Company”), has received Orphan Drug Designation for its LP-310 drug candidate for oral...

Oncocyte Reports Third Quarter 2023 Financial Results

Nov 9, 2023

-Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET- IRVINE, CA, November 09, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023. Third Quarter and Recent Highlights VitaGraft™ Kidney, the Company’s kidney transplant diagnostic test, received a positive coverage decision from CMS coverage; commercial revenue is...

BioStem Technologies Awarded Q Code for VENDAJE AC® Line from Centers for Medicare and Medicaid Services

Nov 8, 2023

POMPANO BEACH, FLORIDA, November 8, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture and commercialization of placental-derived biologics for advanced wound care, today announced that the Centers for Medicare and Medicaid Services (CMS) has published a new Q code, Q4279 for VENDAJE AC® pursuant to its application for Healthcare Common Procedure Coding System (HCPCS) “Q” codes. The HCPCS code assigned for VENDAJE...

Blue Water Petroleum Corp (BWPC) To Showcase Hydrogen Fuel Processing Technology

Nov 8, 2023

CHEYENNE, WY, November 8, 2023 - Blue Water Petroleum Corp’s (OTC PINK: BWPC), wholly owned subsidiary Attimar SA, has developed cutting-edge hydrogen processing technologies which produce sustainable and ecologically viable fuels. These new H2 based fuels represent significant steps towards reducing the global dependency on fossil fuels, as they are designed to completely replace methane gas, which significantly reduces carbon emissions. Blue Water sees this strategic development as...

Digital Utilities Ventures, Inc. (OTC: DUTV) Subsidiary and Nano Gas™ Environmental Agree to Exclusive Global License For Nanobubble Technology in Agriculture and Related Markets

Nov 8, 2023

Mankato, Minnesota, November 8, 2023 - Digital Utilities Ventures, Inc. (OTC: DUTV) announces that Nano Gas Environmental (Nano Gas™) has exclusively licensed the Nano Gas Technologies patents and intellectual property to the public company Digital Utilities Ventures, Inc. future subsidiary of Easy Modular Manufacturing (EMM) for use in the Global Agricultural and related markets (other than a few limited countries). EMM is manufacturing the newest fully automated generation of Nano Gas...

BioStem Technologies to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023

Nov 6, 2023

POMPANO BEACH, FLORIDA, November 6, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced today that it plans to release its third quarter 2023 financial results pre-market on Tuesday, November 14, 2023. BioStem will host a conference call and webcast at 10:30am ET on Tuesday, November 14, 2023. The call will include a discussion of...

BioStem Technologies Closes Oversubscribed $2M Private Placement

Nov 3, 2023

POMPANO BEACH, FLORIDA, November 3, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, today announces that it has closed an oversubscribed private placement of common stock to accredited investors for an aggregate of 1,337,000 units (each, a “Unit”) at a price of $1.50 per Unit for gross proceeds of $2 million. Each Unit consists of one...

Oncocyte to Announce Third Quarter 2023 Financial Results

Nov 3, 2023

Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, November 3, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that the company will host a conference call and webcast on Thursday, November 9, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its third quarter financial results and recent highlights. The third quarter 2023 financial results press release will be issued the same day,...

BioStem Technologies Announces Opening of First Clinical Site for Diabetic Foot Ulcer Study

Oct 24, 2023

Study to support differentiated efficacy of Vendaje® structural tissue allograft POMPANO BEACH, FLORIDA, October 24, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, today announced that the first site is now fully opened for its clinical trial, evaluating the Vendaje® tissue allograft in the treatment of diabetic foot ulcers (DFU). Jason...

Lipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference

Oct 23, 2023

Pittsburgh, PA, October 23, 2023 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our, “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, will present at the 2023 virtual Fall Foliage MicroCap Rodeo Conference to be held from October 24th - 27th. Dr. Jonathan Kaufman, CEO of Lipella, said: “2023 continues to be a year of significant milestone achievements for Lipella. Early in the year, we were delighted to report...

BioStem Technologies to Present at the Fall Foliage MicroCap Rodeo Conference

Oct 18, 2023

POMPANO BEACH, FLORIDA, October 18, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, will present at the 2023 virtual Fall Foliage MicroCap Rodeo Conference to be held from October 24th - 27th. Jason Matuszewski, Chief Executive Officer of BioStem, said, “BioStem has achieved a number of significant milestones in 2023, including the...

BioStem Technologies to Highlight Core Advanced Wound Care Portfolio at SAWC Fall 2023 Conference

Oct 17, 2023

POMPANO BEACH, FLORIDA, October 17, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announced that it will highlight the advantages of its Vendaje® and AmnioWrap2TM portfolios to help patients with difficult to heal chronic wounds at the 2023 Symposium on Advanced Wound Care (SAWC) Fall Conference held November 3rd – 5th in Las...

SELLAS Advances Blood Cancer Treatment with “Tremendous Therapeutic Promise”

Oct 11, 2023

October 11, 2023 SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has reported two significant milestones this week as it pursues development of its drug candidate, SLS009 for hematological malignancies. “SLS009 is a novel and highly selective CDK9 inhibitor which, to date, has shown tremendous therapeutic promise across multiple blood cancers.” Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS The company has dosed the first patient in a Phase Ib/II trial...

BioAdaptives Announces Nationwide Launch of Lung Fortress™ Natural Supplement

Oct 10, 2023

Lung Fortress is a new potent, derivative natural supplement to support pulmonary health amid rising concerns for seasonal increases in respiratory problems LAS VEGAS, NV, October 10, 2023 – BioAdaptives, Inc. (OTC: BDPT), a leading formulator and distributor of innovative, all-natural dietary supplements, today announces the launch of Lung Fortress™, a robust, all-natural supplement formula designed to foster pulmonary health, in response to the anticipated seasonal increases in...

BioStem Technologies: CMS Decision a “Win For Patients”

Sep 29, 2023

POMPANO BEACH, FLORIDA, September 29, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, today hails a decision by the Centers for Medicare & Medicaid Services (CMS) as being in the best interests of patients. Three Medicare Administrative Contractors today announced a decision to withdraw the final local coverage determinations (LCDs)...

BioStem Technologies Takes on Diabetic Foot Ulcers with Innovative Wound Care Product

Sep 26, 2023

“We have already demonstrated scientifically that our process and product is exceptional.” Jason Matuszewski, Chief Executive Officer September 26, 2023 BioStem Technologies (OTC: BSEM) has received Investigational Review Board (IRB) approval for a clinical study that will investigate the utilization and effects of its Vendaje Ⓡ wound care product in diabetic foot ulcers. “We have already demonstrated scientifically that our process and product is exceptional. This study will enhance our...

BioStem Receives IRB Approval for Clinical Study to Evaluate Vendaje® in Diabetic Foot Ulcers

Sep 26, 2023

POMPANO BEACH, FLORIDA, September 26, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced today the approval of an Investigational Review Board (IRB) sanctioned clinical study. This study aims to investigate the utilization and effects of Vendaje in diabetic patients suffering from foot ulcers. “This is a landmark study for...

RemSleep Holdings Inc. Provides an Update on Funding and DeltaWave

Sep 25, 2023

Tampa, FL, September 25, 2023 - RemSleep Holdings Inc. (OTCQB: RMSL), a medical device manufacturer dedicated to forever changing the level of treatment provided to Obstructive Sleep Apnea (OSA) patients, announces a new investor agreement and DeltaWave submission update. RemSleep recently entered into a Purchase Agreement with Janbella Group, LLC which was the subject of an 8K filling dated September 18th and will commence with the registration statement on Form S-1 to be filed by...

SELLAS SLS009 Phase 1 Clinical Study Successfully Achieves All Primary and Secondary Endpoints

Sep 22, 2023

September 22, 2023 Late-stage biopharmaceutical company, SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has announced positive topline data for the patient group with relapsed/refractory (r/r) lymphomas from its Phase 1 dose-escalation trial of its CDK9 inhibitor, SLS009 (GFH009). We are excited to share strong topline data from the Phase 1 trial of SLS009 in lymphoma patients. The data demonstrate meaningful anti-tumor activity and clinical responses as a monotherapy. Based on its...

BioStem Technologies Initiates Nationwide Launch of AmnioWrap2™ with Venture Medical

Sep 19, 2023

Leading wound market solutions provider will lead BioStem’s commercialization of AmnioWrap2™ AmnioWrap2 is a versatile allograft solution for wound applications POMPANO BEACH, FLORIDA, September 19, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placenta-derived biologics for advanced wound care, has entered an agreement with leading US wound market solutions provider, Venture Medical,...

BioStem Technologies Engages PCG Advisory for Strategic Investor Relations

Sep 18, 2023

POMPANO BEACH, FLORIDA, September 18, 2023 - BioStem Technologies Inc. (OTC: BSEM), an innovator in the development, manufacture, and commercialization of allografts for regenerative therapies, has engaged PCG Advisory, Inc., a leading investor relations and digital strategies firm, to serve as an advisor for investor relations and strategic communications. PCG Advisory will work closely with BioStem’s senior management team to build upon the company’s investor relations outreach and deliver a...

Oncocyte’s VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier

Sep 18, 2023

Interventional study compares VitaGraft to current transplant rejection monitoring protocols Oncocyte’s VitaGraft assay detects antibody-mediated transplant rejection 10 months sooner than commonly used monitoring protocols (p<0.001) IRVINE, CA, September 18, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced the presentation of significant new clinical data at the European Society of Organ Transplant (ESOT) conference. The data was generated from a...

Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023

CEO Josh Riggs will be meeting with registered investors on September 11-12, 2023 IRVINE, CA, September 6, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it will participate in the upcoming H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023, at the Lotte New York Palace Hotel. Josh Riggs, CEO of Oncocyte, will be meeting 1x1 with registered investors during the conference. The Company’s virtual presentation...

RemSleep Holdings Inc. Announces Completion of DeltaWave CPAP Mask Testing

Sep 1, 2023

Tampa, FL, September 1, 2023 - RemSleep Holdings Inc. (OTCQB: RMSL), a medical device manufacturer dedicated to forever changing the level of treatment provided to Obstructive Sleep Apnea (OSA) patients, provides an update on its testing protocol for 510K clearance of its DeltaWave CPAP Mask. RemSleep has completed the testing protocol for 510K clearance and all tests have successfully passed including the Cytotoxicity and MLA tests which were the subject of past issues requiring retesting....

Bloomios Reports Q2 2023 Financial Results

Aug 30, 2023

Quarterly Revenue More Than Doubles to $2.7 Million Year-to-Date Revenue up 96% to $5.4 Million SANTA BARBARA, Calif., August 30, 2023 - Bloomios, Inc. (OTCQB: BLMS), a leading white-label and private-label manufacturer and wholesaler of hemp-derived nutraceutical, cosmetics and pet products, reported results for the second quarter ended June 30, 2023. All comparisons are to the same year-ago period unless otherwise noted. Q2 2023 Highlights Revenue totaled $2.7 million, up 111% compared to...

Oncocyte’s VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage

Aug 28, 2023

First digital-droplet PCR assay to receive coverage Expect initial revenue generation in Q1 2024 IRVINE, CA, August 28, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that Palmetto GBA, the Medicare Administrative Contractor for the Centers for Medicare & Medicaid Services (CMS), has issued a positive coverage decision for the Company’s VitaGraft Kidney™ diagnostic test, confirming that the test has met the criteria for coverage under MolDX:...

Oncocyte Reports Second Quarter 2023 Financial Results

Aug 10, 2023

Conference Call on Thursday, August 10, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, August 10, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the second quarter of 2023, ended June 30, 2023. Second Quarter and Recent Highlights Transplant product launch on pace for Q4 early access. Manufacturing transfer process for 48-target universal assay began in June Expanding clinical utility for VitaGraft Kidney, a recent...

ONCOCYTE REGAINS COMPLIANCE WITH NASDAQ LISTING REQUIREMENTS

Aug 9, 2023

IRVINE, CA, August 9, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it has received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance with the Nasdaq minimum bid price continued listing requirement and the matter is now closed. The Company was previously notified by Nasdaq on August 9, 2022 that it was not in compliance with the minimum bid price...

NEWSROOM

Biotechnology

Categories

Tags